Syros Pharmaceuticals Inc [SYRS] stock is trading at $0.20, up 6.05%. An important factor to consider is whether the stock is rising or falling in short-term value. The SYRS shares have gain 17.13% over the last week, with a monthly amount drifted -4.29%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Syros Pharmaceuticals Inc [NASDAQ: SYRS] stock has seen the most recent analyst activity on November 04, 2020, when H.C. Wainwright upgraded its rating to a Buy and also boosted its price target to $15 from $11. Previously, Alliance Global Partners started tracking the stock with Buy rating on September 22, 2020, and set its price target to $18. On January 17, 2020, downgrade downgraded it’s rating to Neutral. ROTH Capital upgraded its rating to Buy for this stock on November 05, 2018. In a note dated March 13, 2018, Wedbush reiterated an Outperform rating on this stock and boosted its target price from $11 to $13.
Syros Pharmaceuticals Inc [SYRS] stock has fluctuated between $0.16 and $7.96 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Syros Pharmaceuticals Inc [NASDAQ: SYRS] shares were valued at $0.20 at the most recent close of the market. An investor can expect a potential return of 2400.0% based on the average SYRS price forecast.
Analyzing the SYRS fundamentals
Syros Pharmaceuticals Inc [NASDAQ:SYRS] reported sales of 0.39M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at -2.29% with Operating Profit Margin at -288.92%, Pretax Profit Margin comes in at -253.41%, and Net Profit Margin reading is -253.41%. To continue investigating profitability, this company’s Return on Assets is posted at -1.15, Equity is -27.47 and Total Capital is -1.97. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -5.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.1860 points at the first support level, and at 0.1758 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.2031, and for the 2nd resistance point, it is at 0.2100.
Ratios To Look Out For
For context, Syros Pharmaceuticals Inc’s Current Ratio is 2.25. On the other hand, the Quick Ratio is 2.25, and the Cash Ratio is 2.05. Considering the valuation of this stock, the price to sales ratio is 13.49.
Transactions by insiders
Recent insider trading involved Flagship Pioneering Fund VII, Affiliate, that happened on Dec 27 ’24 when 1.14 million shares were purchased. Director, AKKARAJU SRINIVAS completed a deal on Dec 30 ’24 to buy 9333.0 shares. Meanwhile, Affiliate Flagship Pioneering Fund VII, bought 1.33 million shares on Dec 27 ’24.
